The ARMCX3 Knockout HeLa Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the expression of ARMCX3. This gene-edited reagent provides a loss-of-function model for investigating ARMCX3-dependent processes in mitochondrial biology, apoptosis, and cell cycle regulation. As a pooled population of edited cells, it preserves heterogeneity while eliminating functional ARMCX3 protein expression across the culture, enabling robust phenotypic analysis without single-cell cloning artifacts.
The host cell line, HeLa, is a human cervical adenocarcinoma epithelial line originally derived in 1951, representing the first immortalized human cell line. It is HPV18-positive and serves as a classic model for cervical carcinoma research, characterized by rapid proliferation, ease of culture, and extensive characterization. These features make it an ideal backdrop for dissecting the mitochondrial functions of ARMCX3 in a tumor-relevant context.
ARMCX3 encodes a mitochondrial outer membrane protein that critically regulates mitochondrial distribution and morphology through its interaction with the MIRO1/TRAK/KIF5 motor adaptor complex. Mechanistically, ARMCX3 bridges mitochondria to kinesin motors via MIRO1 and TRAK1/2, facilitating microtubule-dependent transport. This trafficking influences mitochondrial fission/fusion dynamics mediated by proteins such as DRP1, MFN1, and MFN2. ARMCX3 also modulates apoptotic signaling, potentially through BCL-2 family members, and is implicated in Wnt pathway crosstalk. Upstream, the transcription factor SOX2 may regulate ARMCX3 expression, linking cell identity to mitochondrial homeostasis.
In HeLa cells, disruption of ARMCX3 is expected to alter mitochondrial network organization, impair subcellular energy distribution, and sensitize cells to apoptotic stimuli. Given the oncogenic background driven by HPV18 E6/E7, this knockout model allows dissection of how mitochondrial dynamics and trafficking contribute to tumor cell survival, proliferation, and metastatic behavior. This system is particularly relevant for studying mitochondrial dysfunction in cervical and other cancers, as well as for evaluating mitochondrial-targeted therapeutics.
This polyclonal knockout cell product supports diverse experimental workflows including western blotting and RT-qPCR for expression analysis, MitoTracker-based immunofluorescence for mitochondrial morphology, and functional assays such as MTT for viability, caspase-3/7 activation for apoptosis, and Boyden chamber migration/invasion tests. Interaction studies via co-immunoprecipitation enable mapping of ARMCX3 protein complexes. Applications span cancer cell biology, mitochondrial research, drug screening, and validation of gene function. For further information or custom requests, please contact Ascent Research.
